Pharmacokinetics, safety and efficacy of atazanavir /dolutegravir/lamivudine regimen as maintenance regimen in patients with intolerance and/or resistance to NRTIs, NNRTIs and RTV: a pilot study (PRADA II study)
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Atazanavir (Primary) ; Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms PRADA II
- 30 Mar 2017 Status changed from recruiting to discontinued due to introduction of another integrase inhibitor, recruitement was not feasible anymore.
- 06 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 06 Apr 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.